AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 18569896 — intervention group
Group type: EXPERIMENTAL
Intervention: Maintaining balance coping strategy
Number of subjects: 115
Study 18569896 — intervention group
Group type: EXPERIMENTAL
Intervention: Avoidance coping strategy
Number of subjects: 115
Study 18569896 — intervention group
Group type: EXPERIMENTAL
Intervention: Focusing on caregiving coping strategy
Number of subjects: 115
Study 15748694 — intervention group
Group type: EXPERIMENTAL
Intervention: Ultrasound self-therapy
Number of subjects: 8
Study 15748694 — intervention group
Group type: COMPARATOR
Intervention: Placebo therapy
Number of subjects: 8
Study 12452946 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher dose gum (900 mg CaCO3)
Number of subjects: 24
Study 12452946 — intervention group
Group type: EXPERIMENTAL
Intervention: Lower dose gum (600 mg CaCO3)
Number of subjects: 24
Study 12452946 — intervention group
Group type: EXPERIMENTAL
Intervention: Chewable antacid tablets (1000 mg CaCO3)
Number of subjects: 24
Study 12452946 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 24
Study 12452946 — intervention group
Group type: EXPERIMENTAL
Intervention: Active chewable antacid and gums
Number of subjects: 24
Study 9872843 — intervention group
Group type: EXPERIMENTAL
Intervention: Nocturnal asthma (NA) group
Number of subjects: 21
Study 9872843 — intervention group
Group type: EXPERIMENTAL
Intervention: Alveolar tissue CD4+ cells
Number of subjects: 21
Study 7535996 — intervention group
Group type: EXPERIMENTAL
Intervention: 200‐mL boluses of a 6% hydroxyethyl starch solution
Number of subjects: 60
Study 7535996 — intervention group
Group type: COMPARATOR
Intervention: Standard practices (Control)
Number of subjects: 60
Study 1561645 — intervention group
Group type: EXPERIMENTAL
Intervention: 20% albumin plus crystalloids
Number of subjects: 300
Study 1561645 — intervention group
Group type: COMPARATOR
Intervention: Crystalloids (control group)
Number of subjects: 300
Study 4054196 — intervention group
Group type: EXPERIMENTAL
Intervention: Atenolol 50 mg
Number of subjects: 40
Study 4054196 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40
Study 30759887 — intervention group
Group type: EXPERIMENTAL
Intervention: Fe‐Beans
Number of subjects: 574
Study 30759887 — intervention group
Group type: COMPARATOR
Intervention: Control‐Beans
Number of subjects: 574
Study 28756042 — intervention group
Group type: EXPERIMENTAL
Intervention: Continue Patch
Number of subjects: 701
Study 28756042 — intervention group
Group type: COMPARATOR
Intervention: Discontinue Patch
Number of subjects: 701
Study 27117056 — intervention group
Group type: EXPERIMENTAL
Intervention: Bevacizumab (BEV) continuation as a single agent
Number of subjects: 0
Study 27117056 — intervention group
Group type: COMPARATOR
Intervention: No BEV (treatment holidays)
Number of subjects: 0
Study 27117056 — intervention group
Group type: EXPERIMENTAL
Intervention: Bevacizumab (BEV) continuation
Number of subjects: 0
Study 24632316 — intervention group
Group type: EXPERIMENTAL
Intervention: PBMNC + PNS
Number of subjects: 52
Study 24632316 — intervention group
Group type: COMPARATOR
Intervention: PBMNC
Number of subjects: 52
Study 23403336 — intervention group
Group type: EXPERIMENTAL
Intervention: Maxillary advancement only
Number of subjects: 50
Study 23403336 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined with mandibular setback
Number of subjects: 50
Study 21207496 — intervention group
Group type: EXPERIMENTAL
Intervention: Medicinal leech therapy (MLT)
Number of subjects: 56
Study 21207496 — intervention group
Group type: COMPARATOR
Intervention: Venous catheterization (VC)
Number of subjects: 56
Study 19525451 — intervention group
Group type: EXPERIMENTAL
Intervention: CT plus (18)F‐FDG PET
Number of subjects: 150
Study 19525451 — intervention group
Group type: COMPARATOR
Intervention: CT only
Number of subjects: 150
Study 17694485 — intervention group
Group type: EXPERIMENTAL
Intervention: Rational Rehabilitation
Number of subjects: 19
Study 15468016 — intervention group
Group type: EXPERIMENTAL
Intervention: Tai Chi training
Number of subjects: 28
Study 15468016 — intervention group
Group type: COMPARATOR
Intervention: Wellness education (WE) program
Number of subjects: 28
Study 11789299 — intervention group
Group type: EXPERIMENTAL
Intervention: Dietary supplement containing 67% omega-3 fatty acids (185 mg EPA and 465 mg DHA) in a spread form, 7 grams daily for 12 weeks.
Number of subjects: 52
Study 11789299 — intervention group
Group type: COMPARATOR
Intervention: Olive oil spread (placebo)
Number of subjects: 52
Study 9541192 — intervention group
Group type: EXPERIMENTAL
Intervention: Tamoxifen
Number of subjects: 5
Study 9541192 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 5
Study 7744898 — intervention group
Group type: EXPERIMENTAL
Intervention: Patient-controlled analgesia
Number of subjects: 184
Study 7744898 — intervention group
Group type: COMPARATOR
Intervention: Intramuscular injections
Number of subjects: 184
Study 2143300 — intervention group
Group type: EXPERIMENTAL
Intervention: Akne-Mycyna (1% erythromycin), applied twice daily for at least 3 weeks
Number of subjects: 30
Study 2143300 — intervention group
Group type: EXPERIMENTAL
Intervention: Akne-Mycyna (1% erythromycin)
Number of subjects: 30
Study 6112131 — intervention group
Group type: EXPERIMENTAL
Intervention: Benzodiazepine anxiolytics
Number of subjects: 75
Study 6112131 — intervention group
Group type: EXPERIMENTAL
Intervention: Psychostimulants (amphetamine type)
Number of subjects: 75
Study 6112131 — intervention group
Group type: EXPERIMENTAL
Intervention: Neuroleptics
Number of subjects: 75
Study 6112131 — intervention group
Group type: EXPERIMENTAL
Intervention: Tricyclic antidepressants
Number of subjects: 75
Study 6112131 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 75
Study 31765987 — intervention group
Group type: EXPERIMENTAL
Intervention: S-1, leucovorin, oxaliplatin and gemcitabine (SLOG) regimen
Number of subjects: 73
Study 30149997 — intervention group
Group type: EXPERIMENTAL
Intervention: Ultra-low-dose CT (100Sn kVp, 70 mAs)
Number of subjects: 210
Study 30149997 — intervention group
Group type: COMPARATOR
Intervention: Standard-dose CT (110 kVp, 50 mAs)
Number of subjects: 210
Study 30149997 — intervention group
Group type: EXPERIMENTAL
Intervention: Ultra-low-dose CT
Number of subjects: 210
Study 30149997 — intervention group
Group type: COMPARATOR
Intervention: Standard-dose CT
Number of subjects: 210
Study 28912631 — intervention group
Group type: EXPERIMENTAL
Intervention: Shoulder treatment plus cervicothoracic spinal thrust/non-thrust
Number of subjects: 18
Study 28912631 — intervention group
Group type: COMPARATOR
Intervention: Shoulder treatment-only group
Number of subjects: 18
Study 26371134 — intervention group
Group type: EXPERIMENTAL
Intervention: Fulvestrant 500 mg
Number of subjects: 205
Study 26371134 — intervention group
Group type: COMPARATOR
Intervention: Anastrozole 1 mg
Number of subjects: 205
Study 23681913 — intervention group
Group type: EXPERIMENTAL
Intervention: Slow breathing (6 breaths/min)
Number of subjects: 16
Study 19451435 — intervention group
Group type: EXPERIMENTAL
Intervention: Imatinib (IM) 400 mg daily
Number of subjects: 73
Study 19451435 — intervention group
Group type: EXPERIMENTAL
Intervention: Imatinib (IM) 600 mg daily
Number of subjects: 73
Study 19451435 — intervention group
Group type: EXPERIMENTAL
Intervention: Imatinib (IM) with KIT exon 11 mutations
Number of subjects: 73
Study 17968921 — intervention group
Group type: EXPERIMENTAL
Intervention: High molecular weight cross-linked hylan
Number of subjects: 660
Study 17968921 — intervention group
Group type: EXPERIMENTAL
Intervention: Non-cross-linked medium molecular weight HA of avian origin
Number of subjects: 660
Study 17968921 — intervention group
Group type: EXPERIMENTAL
Intervention: Non-cross-linked low molecular weight HA of bacterial origin
Number of subjects: 660
Study 17968921 — intervention group
Group type: COMPARATOR
Intervention: Hylan
Number of subjects: 660
Study 15084900 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.6 g/kg ethanol
Number of subjects: 61
Study 15084900 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 61
Study 15084900 — intervention group
Group type: EXPERIMENTAL
Intervention: Pleasant and unpleasant slides
Number of subjects: 61
Study 11273587 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose leucovorin (175 mg) with fluorouracil (370 mg/m2)
Number of subjects: 4927
Study 11273587 — intervention group
Group type: COMPARATOR
Intervention: Low-dose leucovorin (25 mg) with fluorouracil (370 mg/m2)
Number of subjects: 4927
Study 11273587 — intervention group
Group type: EXPERIMENTAL
Intervention: Levamisole (50 mg) with fluorouracil and leucovorin
Number of subjects: 4927
Study 11273587 — intervention group
Group type: COMPARATOR
Intervention: Placebo with fluorouracil and leucovorin
Number of subjects: 4927
Study 11273587 — intervention group
Group type: EXPERIMENTAL
Intervention: Weekly treatment regimen
Number of subjects: 4927
Study 11273587 — intervention group
Group type: COMPARATOR
Intervention: Monthly treatment regimen
Number of subjects: 4927
Study 9612276 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.5 IDU.kg‐1.h‐1 CCK
Number of subjects: 7
Study 9612276 — intervention group
Group type: EXPERIMENTAL
Intervention: 1.0 IDU.kg‐1.h‐1 CCK
Number of subjects: 7
Study 9612276 — intervention group
Group type: COMPARATOR
Intervention: Saline (control)
Number of subjects: 7
Study 7834324 — intervention group
Group type: EXPERIMENTAL
Intervention: Loratadine 10 mg
Number of subjects: 30
Study 7834324 — intervention group
Group type: EXPERIMENTAL
Intervention: Loratadine 20 mg
Number of subjects: 30
Study 7834324 — intervention group
Group type: EXPERIMENTAL
Intervention: Terfenadine 120 mg/day for 21 days
Number of subjects: 30
Study 2024862 — intervention group
Group type: EXPERIMENTAL
Intervention: Aerosol pentamidine, 60 mg per dose, delivered via ultrasonic nebulizer, 5 doses over 14 days followed by maintenance of one dose every 2 weeks.
Number of subjects: 162
Study 2024862 — intervention group
Group type: COMPARATOR
Intervention: Placebo, delivered via ultrasonic nebulizer, 5 doses over 14 days followed by maintenance of one dose every 2 weeks.
Number of subjects: 162
Study 2024862 — intervention group
Group type: EXPERIMENTAL
Intervention: Aerosol pentamidine
Number of subjects: 162
Study 2024862 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 162
Study 7416269 — intervention group
Group type: EXPERIMENTAL
Intervention: Hemodialysis, twice weekly for 10 weeks
Number of subjects: 4
Study 7416269 — intervention group
Group type: COMPARATOR
Intervention: Sham dialysis, twice weekly for 10 weeks
Number of subjects: 4
Study 31112026 — intervention group
Group type: EXPERIMENTAL
Intervention: Non-adenocarcinoma pancreatic cancer (NACPC)
Number of subjects: 441
Study 31112026 — intervention group
Group type: COMPARATOR
Intervention: Adenocarcinoma pancreatic cancer (ACPC)
Number of subjects: 441
Study 28866763 — intervention group
Group type: EXPERIMENTAL
Intervention: Standard treatment (StnTx: two servings milk and milk products/day; meet PA guidelines plus weight-bearing PA three times/week)
Number of subjects: 78
Study 28866763 — intervention group
Group type: EXPERIMENTAL
Intervention: Modified treatment (ModTx: four servings milk and milk products/day; meet PA guidelines plus daily weight-bearing PA)
Number of subjects: 78
Study 28866763 — intervention group
Group type: COMPARATOR
Intervention: Control (Ctrl; no intervention)
Number of subjects: 78
Study 26522641 — intervention group
Group type: EXPERIMENTAL
Intervention: Simulated infobutton linked to UpToDate
Number of subjects: 44
Study 26522641 — intervention group
Group type: COMPARATOR
Intervention: Traditional Internet resources
Number of subjects: 44
Study 23578004 — intervention group
Group type: EXPERIMENTAL
Intervention: Acetazolamide 250 mg three times a day for 5 days
Number of subjects: 70
Study 23578004 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 70
Study 21826205 — intervention group
Group type: EXPERIMENTAL
Intervention: Skin conductance responses (SCRs) during observation of pain in others
Number of subjects: 0
Study 21826205 — intervention group
Group type: EXPERIMENTAL
Intervention: Skin conductance responses (SCRs) during self pain
Number of subjects: 0
Study 19728603 — intervention group
Group type: EXPERIMENTAL
Intervention: Microsurgery lumbar discectomy (MSLD)
Number of subjects: 230
Study 19728603 — intervention group
Group type: COMPARATOR
Intervention: Traditional open discectomy by fenestration
Number of subjects: 230
Study 16939522 — intervention group
Group type: EXPERIMENTAL
Intervention: Novel matrix transdermal delivery system of fentanyl
Number of subjects: 24
Study 16939522 — intervention group
Group type: COMPARATOR
Intervention: Durogesic reservoir formulation
Number of subjects: 24
Study 14741301 — intervention group
Group type: EXPERIMENTAL
Intervention: Mechanical perturbation applied to the right foot during paced walking
Number of subjects: 12
Study 14741301 — intervention group
Group type: EXPERIMENTAL
Intervention: Mechanical perturbation applied laterally
Number of subjects: 12
Study 14741301 — intervention group
Group type: EXPERIMENTAL
Intervention: Mechanical perturbation applied medially
Number of subjects: 12
Study 14741301 — intervention group
Group type: EXPERIMENTAL
Intervention: Mechanical perturbation
Number of subjects: 12
Study 11485582 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical application of butylcyanoacrylate
Number of subjects: 101
Study 11485582 — intervention group
Group type: COMPARATOR
Intervention: Polypropylene sutures
Number of subjects: 101
Study 9684388 — intervention group
Group type: EXPERIMENTAL
Intervention: Marijuana users
Number of subjects: 107
Study 9684388 — intervention group
Group type: COMPARATOR
Intervention: Non-marijuana users
Number of subjects: 107
Study 7603076 — intervention group
Group type: EXPERIMENTAL
Intervention: Amlodipine (5-10 mg o.d.)
Number of subjects: 24
Study 7603076 — intervention group
Group type: EXPERIMENTAL
Intervention: Enalapril (10-20 mg o.d.)
Number of subjects: 24
Study 7603076 — intervention group
Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 24
Study 3250868 — intervention group
Group type: EXPERIMENTAL
Intervention: 200 mg ferrous sulphate
Number of subjects: 69
Study 3250868 — intervention group
Group type: EXPERIMENTAL
Intervention: 5 mg riboflavin and 150 mg ascorbic acid
Number of subjects: 69
Study 3250868 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 69
Study 30324561 — intervention group
Group type: EXPERIMENTAL
Intervention: Composite resin (Z250, 3M ESPE)
Number of subjects: 55
Study 30324561 — intervention group
Group type: EXPERIMENTAL
Intervention: Resin Modified Glass Ionomer Cement (Vitremer, 3M ESPE)
Number of subjects: 55
Study 30324561 — intervention group
Group type: COMPARATOR
Intervention: Both materials (Z250 and Vitremer)
Number of subjects: 55
Study 28501361 — intervention group
Group type: EXPERIMENTAL
Intervention: Three cycles of IUI + COH (n = 101)
Number of subjects: 207
Study 28501361 — intervention group
Group type: COMPARATOR
Intervention: One cycle of IVF (n = 106)
Number of subjects: 207
Study 25646352 — intervention group
Group type: EXPERIMENTAL
Intervention: Positive Psychotherapy for Smoking Cessation (PPT-S)
Number of subjects: 66
Study 25646352 — intervention group
Group type: COMPARATOR
Intervention: Standard Treatment (ST)
Number of subjects: 66
Study 23909402 — intervention group
Group type: EXPERIMENTAL
Intervention: L-carnitine (900 mg/day)
Number of subjects: 102
Study 23909402 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 102
Study 20962342 — intervention group
Group type: EXPERIMENTAL
Intervention: Dilute diesel exhaust (particle concentration 300 μg/m³)
Number of subjects: 52
Study 20962342 — intervention group
Group type: COMPARATOR
Intervention: Filtered air
Number of subjects: 52
Study 18704484 — intervention group
Group type: EXPERIMENTAL
Intervention: BCAA supplementation (1.7 MJ day(‐1) high-protein supplement composed of 50% valine, 35% leucine, and 15% isoleucine)
Number of subjects: 12
Study 18704484 — intervention group
Group type: COMPARATOR
Intervention: Control group (standard diet of 14.5 MJ day(‐1) with 58% carbohydrate, 30% fat, and 12% protein)
Number of subjects: 12
Study 18704484 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups (BCAA and Control)
Number of subjects: 12
Study 17039422 — intervention group
Group type: EXPERIMENTAL
Intervention: metformin plus liraglutide
Number of subjects: 144
Study 17039422 — intervention group
Group type: EXPERIMENTAL
Intervention: liraglutide
Number of subjects: 144
Study 14573827 — intervention group
Group type: EXPERIMENTAL
Intervention: Home sampling
Number of subjects: 962
Study 14573827 — intervention group
Group type: COMPARATOR
Intervention: Office sampling
Number of subjects: 962
Study 16948207 — intervention group
Group type: EXPERIMENTAL
Intervention: Elastic support bandage
Number of subjects: 90
Study 16948207 — intervention group
Group type: EXPERIMENTAL
Intervention: Collar and cuff sling
Number of subjects: 90
Study 16948207 — intervention group
Group type: EXPERIMENTAL
Intervention: Elevation on two pillows
Number of subjects: 90
Study 8836219 — intervention group
Group type: EXPERIMENTAL
Intervention: Express saccade makers (ES makers)
Number of subjects: 20
Study 8836219 — intervention group
Group type: COMPARATOR
Intervention: Control subjects
Number of subjects: 20
Study 1486457 — intervention group
Group type: EXPERIMENTAL
Intervention: Dopaminergic therapy (levodopa, bromocriptine)
Number of subjects: 82
Study 1486457 — intervention group
Group type: EXPERIMENTAL
Intervention: Anticholinergic drugs
Number of subjects: 82
Study 6376294 — intervention group
Group type: EXPERIMENTAL
Intervention: External pneumatic calf compression (EPC) applied perioperatively
Number of subjects: 194
Study 6376294 — intervention group
Group type: COMPARATOR
Intervention: Control group (no EPC)
Number of subjects: 194
Study 30182287 — intervention group
Group type: EXPERIMENTAL
Intervention: Cross-education (strength training of the non-operated leg during weeks 1-12 after surgery)
Number of subjects: 43
Study 30182287 — intervention group
Group type: COMPARATOR
Intervention: Standard care (both groups received this after ACL reconstruction)
Number of subjects: 43
Study 30182287 — intervention group
Group type: EXPERIMENTAL
Intervention: Non-injured leg (hop distance)
Number of subjects: 43
Study 29631203 — intervention group
Group type: EXPERIMENTAL
Intervention: Active rTMS (55 trains, 18 Hz, 120% resting motor threshold intensity)
Number of subjects: 43
Study 29631203 — intervention group
Group type: COMPARATOR
Intervention: Sham rTMS
Number of subjects: 43
Study 29631203 — intervention group
Group type: EXPERIMENTAL
Intervention: Active rTMS
Number of subjects: 43
Study 26422745 — intervention group
Group type: EXPERIMENTAL
Intervention: SSE intervention
Number of subjects: 494
Study 26422745 — intervention group
Group type: COMPARATOR
Intervention: Customary care (control)
Number of subjects: 494
Study 24530488 — intervention group
Group type: EXPERIMENTAL
Intervention: NOURISH+MI (Motivational Interviewing)
Number of subjects: 60
Study 24530488 — intervention group
Group type: COMPARATOR
Intervention: NOURISH(+)
Number of subjects: 60
Study 24530488 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 60
Study 22652461 — intervention group
Group type: EXPERIMENTAL
Intervention: Neuromonitoring during thyroid surgery (group A)
Number of subjects: 259
Study 22652461 — intervention group
Group type: COMPARATOR
Intervention: No neuromonitoring during thyroid surgery (control group B)
Number of subjects: 259
Study 20708714 — intervention group
Group type: EXPERIMENTAL
Intervention: Micronutrient and antioxidant preparation
Number of subjects: 218
Study 20708714 — intervention group
Group type: COMPARATOR
Intervention: Standard multivitamins (identical appearing recommended daily allowance multivitamin and mineral preparation)
Number of subjects: 218
Study 17408055 — intervention group
Group type: EXPERIMENTAL
Intervention: Nicardipine 15 microg/kg IV 30 s after induction
Number of subjects: 40
Study 17408055 — intervention group
Group type: COMPARATOR
Intervention: Normal saline (Control)
Number of subjects: 40
Study 16280697 — intervention group
Group type: EXPERIMENTAL
Intervention: HAART plus subcutaneous IL-2
Number of subjects: 148
Study 16280697 — intervention group
Group type: EXPERIMENTAL
Intervention: HAART plus intravenous IL-2
Number of subjects: 148
Study 16280697 — intervention group
Group type: COMPARATOR
Intervention: HAART alone
Number of subjects: 148
Study 12118904 — intervention group
Group type: EXPERIMENTAL
Intervention: Enalapril (20 mg/day)
Number of subjects: 20
Study 12118904 — intervention group
Group type: EXPERIMENTAL
Intervention: Eprosartan (600 mg/day)
Number of subjects: 20
Study 12118904 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of enalapril (10 mg/day) and eprosartan (300 mg/day)
Number of subjects: 20
Study 12118904 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study 10468077 — intervention group
Group type: EXPERIMENTAL
Intervention: Chewed buffered aspirin tablet (325 mg)
Number of subjects: 12
Study 10468077 — intervention group
Group type: EXPERIMENTAL
Intervention: Swallowed whole buffered aspirin tablet (325 mg)
Number of subjects: 12
Study 10468077 — intervention group
Group type: EXPERIMENTAL
Intervention: Buffered aspirin solution (Alka Seltzer)
Number of subjects: 12
Study 7786212 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.1% diclofenac eye drops
Number of subjects: 52
Study 7786212 — intervention group
Group type: COMPARATOR
Intervention: 1% prednisolone eye drops
Number of subjects: 52
Study 2260502 — intervention group
Group type: EXPERIMENTAL
Intervention: Intralesional Hu‐IFN‐alpha (10^5 to 2 x 10^5 IU)
Number of subjects: 9
Study 2260502 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 9
Study 2260502 — intervention group
Group type: EXPERIMENTAL
Intervention: Intralesional Hu‐IFN‐alpha
Number of subjects: 9
Study 462483 — intervention group
Group type: EXPERIMENTAL
Intervention: Single test dose of irradiation
Number of subjects: 21
Study 462483 — intervention group
Group type: EXPERIMENTAL
Intervention: Fractionated test dose of irradiation
Number of subjects: 21
Study 462483 — intervention group
Group type: COMPARATOR
Intervention: Not applicable
Number of subjects: 21
Study 31493216 — intervention group
Group type: EXPERIMENTAL
Intervention: rhAT-gamma (72 IU/kg)
Number of subjects: 0
Study 31493216 — intervention group
Group type: COMPARATOR
Intervention: pAT (60 IU/kg)
Number of subjects: 0
Study 31493216 — intervention group
Group type: EXPERIMENTAL
Intervention: rhAT-gamma (60 IU/kg)
Number of subjects: 0
Study 31493216 — intervention group
Group type: EXPERIMENTAL
Intervention: rhAT-gamma
Number of subjects: 0
Study 28777690 — intervention group
Group type: EXPERIMENTAL
Intervention: Nomograms for overall survival (OS)
Number of subjects: 493
Study 28777690 — intervention group
Group type: EXPERIMENTAL
Intervention: Nomograms for progression-free survival (PFS)
Number of subjects: 493
Study 25736134 — intervention group
Group type: EXPERIMENTAL
Intervention: 20 mg atorvastatin calcium
Number of subjects: 120